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ARTICLE OPEN
Integrated molecular landscape of Parkinson’s disease
C. J. H. M. Klemann1, G. J. M. Martens1, M. Sharma2, M. B. Martens3, O. Isacson4, T. Gasser5, J. E. Visser1,6,7 and G. Poelmans1,8,9
Parkinson’s disease is caused by a complex interplay of genetic and environmental factors. Although a number of independent
molecular pathways and processes have been associated with familial Parkinson’s disease, a common mechanism underlying
especially sporadic Parkinson’s disease is still largely unknown. In order to gain further insight into the etiology of Parkinson’s
disease, we here conducted genetic network and literature analyses to integrate the top-ranked ﬁndings from thirteen published
genome-wide association studies of Parkinson’s disease (involving 13.094 cases and 47.148 controls) and other genes implicated in
(familial) Parkinson’s disease, into a molecular interaction landscape. The molecular Parkinson’s disease landscape harbors four
main biological processes—oxidative stress response, endosomal-lysosomal functioning, endoplasmic reticulum stress response,
and immune response activation—that interact with each other and regulate dopaminergic neuron function and death, the
pathological hallmark of Parkinson’s disease. Interestingly, lipids and lipoproteins are functionally involved in and inﬂuenced by all
these processes, and affect dopaminergic neuron-speciﬁc signaling cascades. Furthermore, we validate the Parkinson’s disease
-lipid relationship by genome-wide association studies data-based polygenic risk score analyses that indicate a shared genetic risk
between lipid/lipoprotein traits and Parkinson’s disease. Taken together, our ﬁndings provide novel insights into the molecular
pathways underlying the etiology of (sporadic) Parkinson’s disease and highlight a key role for lipids and lipoproteins in Parkinson’s
disease pathogenesis, providing important clues for the development of disease-modifying treatments of Parkinson’s disease.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disease, with an estimated prevalence of 0.3%,
affecting 1–2% of people over 60 years of age.1, 2 The pathological
hallmark of PD is loss of dopaminergic (DA) neurons in the
substantia nigra (SN), and the presence of protein aggregates (i.e.,
Lewy bodies) involving synuclein alpha (SNCA) in the residual DA
neurons.3 A number of biological processes that contribute to the
pathogenesis of PD have been identiﬁed, including defects in
mitochondrial function,4 oxidative stress,5 and protein aggrega-
tion.6–8 However, detailed insights into the molecular mechanisms
underlying these processes, and how they interact with each
other, are essentially lacking. In many studies exploring PD
pathogenesis, familial PD genes served as starting point. Thus far,
at least eighteen genetic loci for familial PD have been found, and
twelve familial PD candidate genes have been identiﬁed (ATP13A2,
DJ-1, DNAJC6, EIF4G1, FBXO7, LRRK2, PARK2, PINK1, PLA2G6, SNCA,
SYNJ1, and VPS35) (refs 9, 10). However, as a mutation in one of
these familial genes is found in only 5–10% of the cases, PD
should be considered a predominantly sporadic disease,11, 12 with
both genetic and environmental contributing risk factors. In recent
years, 15 genome-wide association studies (GWASs) have inves-
tigated genetic risk factors for sporadic PD13–26 but the functional
coupling of the proteins encoded by the GWAS-identiﬁed
candidate genes to PD pathophysiology is often not clear. In the
present study, we aimed to identify the core mechanisms
underlying PD pathogenesis by using bioinformatics and exten-
sive literature analyses to integrate (1) the genes corresponding to
the top-ranked single-nucleotide polymorphisms (SNPs) found in
published GWASs of sporadic PD, and (2) other PD candidate
genes (e.g., familial PD genes) into a protein interaction landscape.
This molecular landscape allowed us to identify the speciﬁc
biological processes that are key in PD pathogenesis and provides
clues for the development of novel PD treatment strategies.
RESULTS
Selected PD GWAS genes and genetic network enrichment
analysis
Thirteen of the ﬁfteen published PD GWASs met our inclusion
criteria (Supplementary Table 1) and were used to select a total of
451 PD GWAS candidate genes based on SNPs with p < 0.0001
(Supplementary Table 2). Of the ﬁve most signiﬁcantly enriched
ingenuity pathway analysis (IPA) networks (Supplementary
Table 3), the network with the highest enrichment score (p =
1.00E-44) and the highest number of PD GWAS candidate gene-
encoded proteins (28 proteins) served as the starting point for the
building of the molecular landscape (Supplementary Fig. 1).
Received: 11 August 2016 Revised: 5 February 2017 Accepted: 28 February 2017
1Department of Molecular Animal Physiology, Donders Institute for Brain, Cognition and Behaviour, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University,
Nijmegen, The Netherlands; 2Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany;
3Department of Neuroinformatics, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands; 4Neuroregeneration Research Institute,
McLean Hospital/Harvard Medical School, Belmont, MA, USA; 5Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, and
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; 6Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud
University Medical Center, Nijmegen, The Netherlands; 7Department of Neurology, Amphia Hospital, Breda, The Netherlands; 8Department of Cognitive Neuroscience, Donders
Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands and 9Department of Human Genetics, Radboud University Medical
Center, Nijmegen, The Netherlands
Correspondence: G. Poelmans (Geert.poelmans@radboudumc.nl)
J. E. Visser and G. Poelmans contributed equally to this work.
www.nature.com/npjparkd
Published in partnership with the Parkinson’s Disease Foundation
The molecular landscape of PD
Guided by the most signiﬁcantly enriched genetic network and
extensive literature searches, we built a molecular landscape
consisting of 260 interacting proteins (i.e., encoded by approxi-
mately 58% of the 451 PD GWAS genes, Supplementary Table 2),
128 proteins implicated in PD through other evidence (Supple-
mentary Table 4) and 49 proteins that have not been directly
linked to PD (yet) but have multiple functional interactions within
the landscape (Supplementary Table 4). Approximately one in
three landscape proteins are implicated in PD etiology through at
least two types of evidence.
Supplementary Figures 2 and 3 show all relevant protein
interactions in the PD landscape that are functionally involved in
four main biological processes:oxidative stress response,
endosomal-lysosomal functioning, endoplasmic reticulum (ER)
stress response, and neuron death and immune response.
The Supplementary Information provides a detailed and refer-
enced description of the evidence linking all the proteins in the
landscape. In Supplementary Table 5, we have indicated in which
process(es) each landscape protein exerts its main effect and
where it is located in Supplementary Figs 2 and/or 3.
The above being said, we here give a succinct description of the
four main biological processes and signaling cascades in the PD
landscape that are depicted in Fig. 1. Central in the landscape is
signaling involving lipoproteins—i.e., low-density lipoprotein
(LDL), high-density lipoprotein (HDL) and very low-density
lipoprotein (VLDL)—and their component lipids and metabolites
(e.g., cholesterol, oxysterols, sphingolipids such as ceramide and
sphingosine, and triglycerides). Lipid and lipoprotein signaling
represents the ‘‘common denominator’’ that functionally inte-
grates, regulates and is regulated by the four landscape processes
(Fig. 1a–d). Either by themselves or in combination, deﬁcits or
impairments in any of these four processes—each composed of
multiple signaling cascades—can contribute to the degeneration
and ultimately death of DA neurons.
First, deﬁcits or impairments in dopamine synthesis and—
linked to this—iron metabolism can cause an increased oxidative
stress response (Fig. 1a). Dopamine can be either taken up
through active transport or is newly synthesized in neurons and
can subsequently be re-released (through vesicular exocytosis),
degraded or (auto-)oxidized into neuromelanin (NM). Further, like
Fig. 1 Overview of the molecular landscape of PD. The four main biological processes in the PD landscape—oxidative stress response
(Fig. 1a), endosomal-lysosomal functioning (Fig. 1b), endoplasmic reticulum (ER) stress response (Fig. 1c), and neuron death and immune
response (Fig. 1d)—are depicted. ECM extracellular matrix, ER endoplasmic reticulum, UPR unfolded protein response
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erythrocytes (see below), SN DA neurons have a high-oxygen
demand and express oxygen-carrying hemoglobin.
Through oxidation, cytotoxic heme is released from hemoglobin
and then converted in DA neurons to ferrous iron, Fe(II). Fe(II)
increases oxidative stress and together with free cholesterol—that
is taken up by neurons through lipoproteins (see below)—induces
mitochondrial oxysterol formation. In turn, this causes mitochon-
drial dysfunction and triggers the release of pro-apoptotic
cytochrome c and, eventually, neuron death.
The second main landscape process centers around the (dys)
regulation of endosomal-lysosomal functioning (Fig. 1b). Neuronal
uptake of cholesterol occurs through the endosomal system, i.e.,
after neuronal uptake through vesicular endocytosis, LDL particles
are processed into their composite parts: proteins, free cholesterol
and other lipids. Free cholesterol and Fe(II) are bound in
complexes by NM, which are then stored in lysosomes through
autophagy. Hence, NM complex formation prevents the above
described Fe(II)- and cholesterol-induced oxidative stress
response. Moreover, their ageing-related increase in NM content
and the associated increased demands on lysosomal function
renders DA neurons particularly vulnerable to lysosomal defects.
Other important lysosomal functions include the degradation of
misfolded or aggregated proteins (such as pathological SNCA
aggregates), the regulation of ceramide metabolism and reverse
cholesterol transport, i.e., the vesicle-mediated transport and
exocytosis of cholesterol into HDL particles in the bloodstream
(and back to the liver). As such, a defect in any of these
endosomal-lysosomal system components results in disturbed
levels of lipids such as cholesterol and ceramide. In turn, these
disturbed lipid levels affect membrane function in general and
more speciﬁcally the functioning of so-called lipid rafts—micro-
domains of the vesicular, lysosomal, and plasma membrane
containing high amounts of cholesterol and sphingolipids and
crucial for membrane function—and hence processes such as
autophagy, endo- and exocytosis. Deﬁcient lysosomal function
together with reduced degradation by the proteasome also leads
to misfolded or aggregated protein formation.
Misfolded/aggregated proteins trigger the ER stress response
(Fig. 1c), the third main landscape process, and subsequent
activation of the protective unfolded protein response (UPR) as
well as stimulation of cholesterol inﬂux through upregulating the
expression of key lipoprotein receptors. Prolonged ER stress that
can no longer be counteracted by the UPR induces mitochondrial
dysfunction, which eventually results in DA neuron death.
Lastly, apart from or in addition to dysregulated processes
within DA neurons (as described above), DA neuron death can be
the consequence of external factors such as an exaggerated
immune response (Fig. 1d), the fourth landscape process. In this
respect, immune cells are activated and attracted to damaged or
already dying DA neurons by extracellular factors such as the
sphingolipid-derived sphingosine-1-phosphate (S1P), triglyceride-
rich extraneuronal VLDL particles (not shown), heme-oxidized LDL
(oxLDL, see above), and various cytokines. Subsequently, the
damaged/dying DA neurons are removed by the activated
immune cells, an essentially normal and adequate response that
is exaggerated in PD by DA neuron-speciﬁc antigens such as SNCA
aggregates and NM complexes—released by dying DA neurons—
creating a vicious cycle of DA neuron death and immune cell
activation.
Polygenic risk score (PRS) analyses
Because our molecular landscape pointed towards an important
role for lipids and lipoproteins in PD etiology (see above), we
conducted PRS analyses using the tool PRSice,27 with GWAS data
for the blood levels of various lipids and lipoproteins28 as base
samples and meta-analytic PD GWAS data from the International
Parkinson Disease Genomics Consortium (IPDGC)29 as target
sample. We found statistically signiﬁcant evidence (false discovery
rate (FDR)-corrected p < 0.05) for a shared genetic etiology
between the lipid traits ‘‘total cholesterol levels’’ and ‘‘total
triglyceride levels’’ and PD, with the most predictive p-value
threshold (pT) at 0.001 and 0.05, respectively (Fig. 2). In contrast,
the lipoprotein traits ‘‘total HDL levels’’ and ‘‘total LDL levels’’
yielded no evidence for a shared genetic risk with PD (Fig. 2). For
the various combinations of increased or decreased HDL and LDL
levels, we found signiﬁcant evidence for a shared genetic etiology
between PD and the combined trait ‘‘increased HDL + increased
LDL’’ (most predictive pT = 0.05) (Supplementary Fig. 4).
DISCUSSION
In this study, we integrated the available genetic and expression
data with data about environmental risk factors into a protein
interaction landscape that reveals the main biological processes
and signaling cascades that are affected in PD and occur in DA
neurons and immune cells. Our PD landscape represents
processes and cascades that are affected in both the monogenic,
familial and the more prevalent polygenic, sporadic forms of PD. In
this respect, the molecular landscape includes the ‘‘classic’’
processes and cascades known to be affected in PD that are
based on the familial PD candidate genes (e.g., SNCA, PARK2,
LRRK2): mitochondrial function, oxidative stress and protein
aggregation. In addition, the landscape harbors more novel
processes that have been less well studied in relation to PD
pathogenesis yet, such as impairments in lysosomal function and
immune response regulation. The landscape does not imply a
‘‘sequence of events’’ that leads to DA neuron loss, i.e., a number
of (impaired) biological processes and cascades that occur in a
temporally and/or spatially distinct order. Instead, deﬁcits in any of
the main landscape processes/cascades, either by themselves or in
combination with deﬁcits of other processes/cascades, may cause
DA neurons to die. Moreover, an aging-related decline in the
functionality and/or efﬁciency of landscape processes/cascades
may play a role in PD onset and progression. For example, a
gradual buildup of NM or aggregated proteins may disturb
lysosomal function in DA neurons30 or an age-related decrease in
the expression and activity of ER folding enzymes can compro-
mise proper protein folding.31
Lipid and lipoprotein signaling functionally integrates, regulates
and is regulated by the key landscape processes and cascades.
Any disturbance of these processes and cascades can (eventually)
result in DA neuron death, which is further aggravated or initiated
by an increased (auto-)immune response.32 The involvement of
deﬁcient lipid and lipoprotein signaling in PD pathophysiology is
corroborated by a number of environmental risk factor studies.
Increased plasma levels of total cholesterol are associated with a
lower PD risk.33–35 Nevertheless, a recent meta-analysis did not
show an effect of higher or lower dietary cholesterol intake on PD
risk,36 suggesting that direct cholesterol intake through food may
not play a major role in PD etiology. Further, low plasma levels of
LDL are linked to a higher PD risk,37, 38 whereas high-plasma HDL
and CSF oxysterol levels are associated with increased PD risk and
duration.39, 40 In addition, the levels of oxidized LDL, oxysterols and
sphingolipids are increased in the plasma of PD patients.41–43
Thus, PD patients have a lower LDL:HDL ratio that is associated
with a lower risk of cardiovascular disease (CVD)44 and could at
least to some extent explain why the PD population is indeed less
susceptible to developing CVD.39 Apart from the observed
dysregulated levels of cholesterol (metabolites) and cholesterol-
containing lipoproteins in PD patients, lower serum levels of
triglycerides—which are highly enriched in VLDL particles—
associate with an increased PD risk.45, 46
Intriguingly, we found a signiﬁcant overlap between the
polygenic risk associated with total cholesterol and triglyceride
levels and PD. We also identiﬁed a shared genetic etiology
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between the combined lipoprotein trait ‘‘increased HDL +
increased LDL’’ and PD. To our knowledge, we are the ﬁrst to
ﬁnd a shared genetic risk between quantitative traits and a
neurodegenerative disease but these ﬁndings need to be
replicated in larger data sets, especially for the target sample,
i.e., the PD GWAS data set. Together, the epidemiological and our
PRS analysis ﬁndings indicate that the link between speciﬁc lipid/
lipoprotein traits and PD may be the result of both shared
environmental and genetic risk factors.
Given the converging evidence for lipid and lipoprotein
signaling playing a key role in PD etiology, compounds that
modulate lipid/lipoprotein levels could represent effective novel
PD treatments. In this respect, statins—inhibitors of peripheral
cholesterol synthesis that are used to treat hypercholesterolemia
and hence prevent cholesterol-associated CVD—have a neuro-
protective effect in the rat brain,47 but their effect on PD risk
remains unclear.48–55 Interestingly, the only published prospective
study that has adjusted for baseline cholesterol levels before statin
treatment has found that statin use is associated with a
signiﬁcantly higher PD risk,35 which is in keeping with the
observation that higher total plasma cholesterol levels—which are
lowered by statins—are protective against PD. Other signaling
molecules from the landscape that affect cholesterol and
lipoprotein levels are testosterone and vitamin D3. Caucasian
male PD patients show signiﬁcantly reduced testosterone
levels,56–58 and free testosterone levels are positively correlated
Fig. 2 Bar plots from PRSice for shared genetic etiology between four lipid and lipoprotein traits (cholesterol, triglyceride, HDL, and LDL
levels) and PD showing results at broad p-value thresholds (pT). The numbers above the bars indicate the p-values for shared genetic etiology,
and these p-values were corrected using the false discovery rate (FDR) method; *denotes FDR-corrected p< 0.05, **denotes FDR-corrected p<
0.01
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with LDL, HDL, and total cholesterol levels.59 Therefore, decreased
testosterone levels may impact on several key PD landscape
processes, as testosterone regulates the efﬂux of LDL and HDL to
the circulation.60 Hence, testosterone could be used for treating
PD in male patients and indeed, testosterone treatment has some
modest beneﬁcial effects in men with PD.61, 62 Deﬁciency of
vitamin D3—which affects cholesterol metabolism through down-
regulating SREBF1 (ref. 63), the main transcriptional activator of
lipid homeostasis and key landscape protein—has been consis-
tently associated with an increased PD risk64 and its supplementa-
tion may stabilize PD symptoms.65
Lastly, a number of landscape proteins that both regulate lipid/
lipoprotein signaling and landscape cascades involved in DA
neuron death represent attractive (novel) drug targets for PD.
Examples include HMOX1 that prevents oxidative stress by heme,
PSAP and its receptor GPR37 that mediate ceramide metabolism,
the immunity-related ICAM1 that is regulated by extracellular
lipids and (oxidized) lipoproteins, and plasmin that regulates the
degradation of extracellular SNCA and (lipo)proteins.
In conclusion, our integrated molecular landscape yields
detailed insights into the mechanisms underlying PD pathogen-
esis, and highlights the involvement of deﬁcient lipid and
lipoprotein signaling. These ﬁndings warrant future rigorous
perturbation experiments in PD cell and animal models that
may eventually provide validated drug target ‘‘leads’’ for the
development of novel disease-modifying PD treatments.
METHODS
PD GWAS gene selection
The ﬁrst step of our molecular landscape building approach66–68 is the
selection of candidate genes based on GWAS SNPs and their correspond-
ing p-values. All 15 PD GWASs published to date were considered. Criteria
for inclusion were a publicly available GWAS discovery sample with all
SNPs associated at p < 0.0001. From the GWASs for which these data were
available, we then selected the SNPs that were associated with PD at p <
0.0001 to compile a list of associated genes. The selected genes either
contained a SNP that was located within an exonic, intronic or untranslated
region of the gene or were found within 100 kilobases (kb) downstream
and upstream of the SNP. The latter was based on the fact that the vast
majority of expression quantitative trait loci (eQTL) for a given gene are
located within 100 kb downstream and/or upstream of a gene69–71 and
because trait-associated SNPs are more likely to be eQTL.72 The chosen
cutoff for association (p < 0.0001) is often employed to designate
‘‘suggestive’’ association and has been used in GWASs of multiple
disorders.73–75 Subsequently, the literature was searched for additional
(genetic) evidence linking the selected GWAS candidate genes to PD.
Genetic network enrichment analysis
To identify enriched protein networks in the PD GWAS candidate genes, a
network analysis using the IPA software package (http://www.ingenuity.
com) was performed with default parameters, i.e., the analysis used the so-
called reference set of known genes and endogenous chemicals. This
reference set is accessible through the ‘‘Ingenuity Knowledge Base’’, a
repository of data from publicly accessible databases (e.g., BioGRID, IntAct)
and data that are manually curated by Ingenuity through systematically
reviewing published literature. In this respect, of all protein–protein
interactions between the PD candidate proteins in the most signiﬁcantly
enriched IPA network shown in Supplementary Fig. 1 (see Results), we
found approximately 4/5 through publicly accessible databases and 1/5 by
IPA. In addition, only functional relationships that are corroborated by
experimental evidence were included in the IPA networks. For each
network, the Ingenuity software also generates an enrichment score that
takes into account the number of eligible molecules/proteins in the
network and its size, as well as the total number of network-eligible
molecules analyzed and the total number of molecules in the Ingenuity
Knowledge Base that could potentially be included in networks. This score
is the negative logarithm of the right-tailed Fisher’s exact test result.
Molecular landscape building
Following the network enrichment analysis, the literature was extensively
searched for the functions and interactions of all proteins encoded by the
candidate genes implicated through PD GWASs as well as other PD
candidates implicated via other evidence, including genetic association
studies, messenger RNA/protein expression studies and/or functional
studies. First, we used the UniProt Protein Knowledge Base (http://www.
uniprot.org/uniprot)76 to gather basic information on the functions of all
candidate genes and their encoded proteins. Subsequently and starting
with the interactions in the most enriched genetic network, we used
PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) to search for all func-
tional, experimental evidence-based interactions between all PD candidate
genes/proteins. While building the landscape in this way, we also included
genes/proteins and metabolites that have no known link with PD, but have
multiple—i.e., at least two different—functional interactions with PD-
implicated proteins. Based on all gathered information, we generated a
protein interaction landscape. The ﬁgures depicting this landscape were
made using the drawing program Serif DrawPlus version 4.0 (www.serif.
com).
PRS analyses
Our molecular landscape pointed towards an important role for lipids and
lipoproteins in PD etiology (see below). Therefore, we conducted PRS
analyses using the tool PRSice,27 with summary statistics data from GWASs
of blood levels of total cholesterol, total triglycerides, total HDL and total
LDL as ‘‘base’’ samples (GWAS data for 188577 European-ancestry
individuals from the general population)28 and summary statistics data
from a meta-analytic PD GWAS by the IPDGC as ‘‘target’’ sample (GWAS
data for 5333 PD cases and 12,019 healthy control subjects, all of European
ancestry)29. Using the default settings in PRSice we calculated the shared
genetic etiology between the four lipid/lipoprotein traits and PD at seven
broad p-value thresholds (indicated by pT), which were used to select the
SNPs from the base sample that were included in the PRS analysis, i.e., pT <
0.001, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5. As such, the seven pT thresholds led to
the selection of all SNPs that were associated with the base lipid/
lipoprotein phenotype at p < 0.001, 0.05, 0.1 etc.
The calculated p-values indicating the signiﬁcance of a shared genetic
etiology between each lipid/lipoprotein trait and PD were aggregated and
corrected for multiple comparisons using the FDR method, incorporating
potential dependencies between p-values.77
To calculate the FDR, we used the mafdr function in MATLAB (R2012a,
The Mathworks, Natick, MA, USA) using the bootstrap selection method for
the FDR parameter lambda. FDR was set to not lower p-values below
uncorrected p-values, which would have occurred due to overall (relatively)
low uncorrected p-values.
In addition to calculating the shared genetic etiology between the four
lipid/lipoprotein traits and PD, we performed similar analyses using four
‘‘combined lipoprotein traits’’. In order to do this, we ﬁrst divided the HDL
and LDL level summary statistics GWAS data into four groups of SNPs, i.e.,
all SNPs associated with (1) increased HDL levels, (2) increased LDL levels,
(3) decreased HDL levels, and (4) decreased LDL levels (where ‘‘increased’’
and ‘‘decreased’’ refer to all SNPs that had an effect size-indicating beta > 0
and beta < 0, respectively). Subsequently, we conducted PRSice analyses
with four combined data sets as base sample, i.e., (1) all SNPs increasing
HDL and LDL levels, (2) all SNPs decreasing HDL and LDL levels, (3) all SNPs
increasing HDL and decreasing LDL levels, and (4), all SNPs decreasing HDL
and increasing LDL levels. Before the data sets were fed into PRSice, an
equivalent, weighted p-value for each SNP in each of the four combined
HDL/LDL data sets was calculated as: 2peq ¼
1
pHDL
þ 1pLDL
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